Search results
Results from the WOW.Com Content Network
Sales of Dupixent, Sanofi’s blockbuster eczema drug, rose 29.2% to 3.30 billion euros. Reuters notes that the drug on which Sanofi partners with Regeneron Pharmaceuticals Inc ...
Sales of Dupixent, Sanofi’s blockbuster eczema drug, rose 23.8% to 3.48 billion euros. ... Sanofi forecasts Beyfortus sales for the fourth quarter to be similar to the third quarter.
Net sales increased by 11.3% at constant exchange rates to 41.1 billion euros, driven by our new product launches, including Beyfortus that became a blockbuster, as well as Dupixent that exceeded ...
(Reuters) -Sanofi on Thursday raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected sales of new launches helped its second-quarter ...
Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.
Regeneron's anti-inflammatory drug, Dupixent, posted quarterly sales of $3.56 billion, beating estimates of $3.47 billion. The company's French partner Sanofi records Dupixent sales, and profits ...
It has anticipated steeper growth in Dupixent sales in 2025 after the launch for COPD in the country. Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to generate more than ...
The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.